New Schizophrenia Drug Offers Hope
The New York Times:
The drug had reduced schizophrenic symptoms, validating the efforts of hundreds of scientists, inside and outside of Lilly, who had labored together for almost two decades trying to unravel the disorder's biological underpinnings.
The trial results were a major breakthrough in neuroscience, says Dr. Thomas R. Insel, director of the National Institute of Mental Health. For 50 years, all medicines for the disease had worked the same way -- until Dr. Schoepp and other scientists took a different path.